Skip to main content
Premium Trial:

Request an Annual Quote

Miragen Issued Notice of Allowance for microRNA-Related IP

Premium

Miragen Therapeutics this week announced that it has received a notice of allowance from the US Patent and Trademark Office for a patent application covering microRNAs that modulate smooth muscle proliferation and differentiation.

Specifically, the intellectual property claims methods of use in modulating miR-143, which the company said plays a critical role in controlling smooth muscle cells at the site of vascular injury.

Studies conducted by Miragen with collaborators at the University of Texas Southwestern Medical Center in a carotid artery ligation model demonstrated that “injection of synthetic mimics of miR-143 stopped blood vessel blockage by inhibiting stenosis at the site of vessel injury,” Miragen said.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.